{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01843387",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSB-DN001"
      },
      "Organization": {
        "OrgFullName": "Mesoblast, Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy",
      "OfficialTitle": "A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2016",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2015",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 23, 2013",
      "StudyFirstSubmitQCDate": "April 25, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 30, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 12, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 14, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mesoblast, Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.",
      "DetailedDescription": "This study is taking place in Melbourne, Australia."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Diabetic Nephropathy",
          "Type 2 Diabetes"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Diabetic nephropathy",
          "Chronic kidney disease",
          "Metabolic disease",
          "Diabetes mellitus, type 2"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cohort 1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Precursor Cells (MPCs)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Cohort 2",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Precursor Cells (MPCs)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Precursor Cells (MPCs)",
            "InterventionDescription": "Single Intravenous Infusion of MPCs Dose 1 or Placebo",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cohort 1"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Precursor Cells (MPCs)",
            "InterventionDescription": "Single Intravenous Infusion of MPCs Dose 2 or Placebo",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cohort 2"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The primary objective of the study is to assess the safety and tolerability of MPC therapy",
            "PrimaryOutcomeDescription": "Outcomes include the following safety parameters:\n\nNumber of and percent of subject with adverse events and serious adverse events\nClinically significant values and shifts from baseline in vital signs, physical examinations and electrocardiograms\nClinical laboratory tests (hematology, chemistry and urinalysis, flow cytometry with Class I and Class II PRA % with specificity)",
            "PrimaryOutcomeTimeFrame": "60 Weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Exploratory assessment of the efficacy of MPC therapy",
            "SecondaryOutcomeDescription": "Outcomes include changes from baseline at 12 weeks in the following parameters:\n\nRenal function (glomerular filtration rate, renal blood flow)\nSerum creatinine\nUrinary albumin and protein excretion\nGlycemic control\nBiomarkers",
            "SecondaryOutcomeTimeFrame": "12 Weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMen and women who are ≥ 50 and ≤ 85 years old\nSubjects diagnosed with type 2 diabetes at least 2 years prior to Screening\nSubjects with diabetic nephropathy and CKD stage 3b-4\nAlbumin-to-creatinine ratio (ACR) from a spot urine sample >30 and < 3000 mg/g at Screening\nSubjects must be receiving standard of care treatment for their diabetic nephropathy with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin II receptor blocker (ARB) for at least 12 weeks prior to Screening.\nHbA1c < 10.0% at Screening\n\nExclusion Criteria:\n\nPrior participation in any stem cell study\nWomen of childbearing potential\nPotentially unreliable subjects and those judged by the Investigator to be unsuitable for the study\nHistory of active substance abuse (including alcohol) within the past 2 years. Current alcohol abuse is defined as daily consumption of >3 alcoholic beverages (i.e. > 21 alcoholic beverages per week)\nBody weight >150 kg\nSubjects with non-diabetic renal disease e.g. known polycystic kidney disease\nSubjects with a history of a renal transplant or who have had prior dialysis within 3 months of Screening and/or have not maintained a stable level of kidney function within 3 months of Screening\nCurrent or history within 6 months of Screening of NYHA Class III or IV heart failure\nMyocardial infarction or stroke within 6 months prior to Screening\nAny concurrent medical condition/disorder or clinically symptomatic cardiovascular, gastrointestinal, hematological, pulmonary, acute or chronic infectious disease, active retinal disease or other disorder which in the Investigator's opinion would interfere with the subjects ability to complete the trial, would require administration of treatment that could affect the interpretation of the efficacy and safety variables or would preclude safe involvement in the study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "K Segal, PhD",
            "OverallOfficialAffiliation": "Mesoblast, Ltd.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Monash Universtiy",
            "LocationCity": "Clayton",
            "LocationCountry": "Australia"
          },
          {
            "LocationFacility": "Melbourne Renal Research Group",
            "LocationCity": "Melbourne",
            "LocationCountry": "Australia"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "27743903",
            "ReferenceType": "derived",
            "ReferenceCitation": "Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine. 2016 Oct;12:263-269. doi: 10.1016/j.ebiom.2016.09.011. Epub 2016 Sep 17."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007674",
            "ConditionMeshTerm": "Kidney Diseases"
          },
          {
            "ConditionMeshId": "D000003928",
            "ConditionMeshTerm": "Diabetic Nephropathies"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003920",
            "ConditionAncestorTerm": "Diabetes Mellitus"
          },
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000048909",
            "ConditionAncestorTerm": "Diabetes Complications"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafAsFound": "Nephropathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6275",
            "ConditionBrowseLeafName": "Diabetic Nephropathies",
            "ConditionBrowseLeafAsFound": "Diabetic Nephropathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25157",
            "ConditionBrowseLeafName": "Diabetes Complications",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          }
        ]
      }
    }
  }
}